ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2013
Adalimumab for juvenile idiopathic arthritis-associated uveitis.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review.Drug design, development and therapy · 2018Pooled it
- Diagnosis and treatment of uveitis associated with juvenile idiopathic arthritis.Medicine and pharmacy reports · 2021Article
- Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis.Eye (London, England) · 2019Article
- Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.Annals of the rheumatic diseases · 2018Article
- Outcome of Juvenile Idiopathic Arthritis Associated Uveitis in Two Disease Subtypes.Archives of rheumatology · 2017Article
- An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.Current treatment options in rheumatology · 2017Article
- Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017Article
- Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers.Rheumatology (Oxford, England) · 2016Observational
- The Use of Biologic Therapies in Uveitis.Clinical reviews in allergy & immunology · 2015Review
- Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment.Clinical reviews in allergy & immunology · 2015Review
- Systemic adalimumab induces peripheral corneal infiltrates: a case report.BMC ophthalmology · 2015Article
- Treatment of uveitis associated with juvenile idiopathic arthritis.Current rheumatology reports · 2014Review
- Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series.BMC research notes · 2014Article
- Pediatric uveitis: new and future treatments.Current opinion in ophthalmology · 2013Review
- Systemic treatments for noninfectious vitreous inflammation.Mediators of inflammation · 2013Review
- Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Mediators of inflammation · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the long-term outcomes and complications of patients with uveitis from juvenile idiopathic arthritis (JIA) treated with adalimumab.
methodsProspective interventional case series. All patients who underwent treatment with adalimumab for JIA and anterior uveitis were prospectively included in the study. The anterior chamber inflammation was evaluated according to the Standardization of Uveitis Nomenclature criteria.
resultsTwenty-one patients (16 females, five males, 38 eyes) were included in the study. Mean age of patients at referral was 11.1 ± 3.8 (5-17) years. Before initiation of treatment, mean duration of arthritis was 7.0 ± 5.5 (median, 6) months, mean duration of uveitis was 7.0 ± 4.4 (median, 7) months. Oligoarticular arthritis was present in 15 cases (71 %), polyarticular arthritis in six cases (28 %). After a mean follow-up of 18.2 ± 7.7 (9-41) months, resolution of anterior chamber inflammation was obtained in 29/38 eyes (76 %). The anterior uveitis flare rate during the 12 months prior to enrollment was 1.6 ± 0.4/year, and was reduced during adalimumab treatment to 0.7 ± 0.3/year (p<0.001). A significant decrease of the number of relapses/month was present after onset of treatment with adalimumab (0.18 ± 0.2 before versus 0.02 ± 0.1 after treatment onset, p<0.001). No significant correlation was found between relapse number and age, sex, type of JIA and doses of previous steroid treatment (p>0.05).
conclusionAdalimumab showed to be effective and relatively safe for treatment of JIA-associated uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.